Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics (Nasdaq: TRDA) has appointed Dr. Bernhardt “Bernie” Zeiher to its Board of Directors. Previously, Dr. Zeiher was the Chief Medical Officer at Astellas Pharma, where he played key roles in developing numerous therapeutic products. His extensive experience in clinical and regulatory affairs is expected to benefit Entrada as it progresses its lead drug programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1. Dr. Zeiher expresses enthusiasm for joining during this growth phase, emphasizing his alignment with Entrada’s mission to innovate in intracellular therapeutics.
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company, announced participation of CEO Dipal Doshi in a virtual fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023 at 9:00 a.m. ET. This event aims to highlight Entrada's innovative approach to Endosomal Escape Vehicle (EEV™) therapeutics, which targets previously inaccessible intracellular areas for drug delivery. Interested stakeholders can access the live webcast on Entrada's Investor Relations page, with a replay available for 90 days post-event.
Entrada is developing therapies for various diseases, including neuromuscular and immunological conditions, with specific focus on treatments for Duchenne muscular dystrophy.
Entrada Therapeutics (TRDA) has announced a collaboration with Vertex to develop Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1. The company is actively addressing the FDA's clinical hold on its IND application for ENTR-601-44 and has selected ENTR-601-45 as a new therapeutic candidate for Duchenne muscular dystrophy. Following the Vertex collaboration, Entrada's cash runway has been extended into the second half of 2025. Financial results for Q4 2022 reveal a net loss of $24.6 million, up from $18.4 million in Q4 2021, with cash and equivalents totaling $188.7 million, down from $291.1 million a year prior.
Entrada Therapeutics (Nasdaq: TRDA) recently announced that its President and CEO, Dipal Doshi, will participate in the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The conference aims to discuss advancements in healthcare, particularly in biotechnology. A live webcast of the panel will be accessible on Entrada's Investor Relations website, with a replay available for 90 days post-event. Entrada specializes in Endosomal Escape Vehicle (EEV™) therapeutics, targeting previously inaccessible diseases, with a focus on neuromuscular disorders.
Entrada Therapeutics (Nasdaq: TRDA) has announced the successful closing of its strategic collaboration with Vertex following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes a $224 million upfront payment and a $26 million equity investment. Entrada could earn up to $485 million in milestone payments and royalties on future product sales. The collaboration focuses on ENTR-701, a candidate for treating myotonic dystrophy type 1 (DM1), and extends the company’s cash runway into the second half of 2025, enabling further development of its Endosomal Escape Vehicle (EEV™)-therapeutics.
Entrada Therapeutics announces the selection of ENTR-601-45 as a new clinical candidate for treating individuals with Duchenne muscular dystrophy who are amenable to exon 45 skipping. The biopharmaceutical company plans to submit an Investigational New Drug (IND) application in the second half of 2024. Initial studies demonstrate over 90% exon skipping in a hDMD mouse model. The company aims to address a significant unmet need in the Duchenne community and will present further data at the Muscular Dystrophy Association Clinical Conference in March 2023.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced a clinical hold from the FDA on its IND application for ENTR-601-44, aimed at treating Duchenne muscular dystrophy. The FDA's formal Clinical Hold letter will be issued within 30 days. CEO Dipal Doshi expressed disappointment but is committed to addressing the FDA's concerns. The hold is significant as there are currently no approved therapies for patients with exon 44 skippable mutations in Duchenne. Further updates will follow as Entrada engages with the FDA.
Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of $224 million along with $26 million in equity and is eligible for future milestone payments totaling up to $485 million. The collaboration focuses on Entrada’s late-stage preclinical candidate, ENTR-701, which aims to address underlying causes of DM1. Vertex will lead further development, manufacturing, and commercialization efforts.
Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 3:55 PM ET. This event highlights Entrada's commitment to revolutionizing medicine through its Endosomal Escape Vehicle (EEVTM) therapeutics, targeting previously inaccessible intracellular diseases. The chat will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days post-event.
Entrada Therapeutics (Nasdaq: TRDA) reported financial results for Q3 2022, with a net loss of $25.1 million compared to $14.4 million in Q3 2021. As of September 30, 2022, the company had $216 million in cash and equivalents, projected to fund operations into 2H 2024. The company is on track to submit an IND for ENTR-601-44 for Duchenne muscular dystrophy by Q4 2022 and plans to initiate a single ascending dose study in 2023. R&D expenses rose to $19 million from $10.5 million a year prior, driven by increased preclinical study investments.